

Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice

Lydie Viatte, Gaël Nicolas, Dan-Qing Lou, Myriam Bennoun, Jeanne-Claire Lesbordes-Brion, François Canonne-Hergaux, Kai Schönig, Hermann Bujard, Axel Kahn, Nancy C. Andrews, and Sophie Vaumont

We report the generation of a tetracycline-regulated (Tet ON) transgenic mouse model for acute and chronic expression of the iron regulatory peptide hepcidin in the liver. We demonstrate that short-term and long-term tetracycline-dependent activation of hepcidin in adult mice leads to hypoferrremia and iron-limited erythropoiesis, respectively. This clearly establishes the key role of hepcidin in regulating the extracellular iron concentration. We previously demonstrated that, when expressed early in fetal development, con-

stitutive transgenic hepcidin expression prevented iron accumulation in an *Hfe*^{-/-} mouse model of hemochromatosis. We now explore the effect of chronic hepcidin expression in adult *Hfe*^{-/-} mice that have already developed liver iron overload. We demonstrate that induction of chronic hepcidin expression in 2-month-old *Hfe*^{-/-} mice alters their pattern of cellular iron accumulation, leading to increased iron in tissue macrophages and duodenal cells but less iron in hepatocytes. These hepcidin-induced changes

in the pattern of cellular iron accumulation are associated with decreased expression of the iron exporter ferroportin in macrophages but no detectable alteration of ferroportin expression in the hepatocytes. We speculate that this change in iron homeostasis could offer a therapeutic advantage by protecting against damage to parenchymal cells. (Blood. 2006;107:2952-2958)

© 2006 by The American Society of Hematology

Introduction

Although iron is essential for many cellular processes, particularly for mammalian erythropoiesis, iron in excess can be deleterious as it triggers production of free radicals. To maintain iron homeostasis, there is tight regulation of iron absorption by the duodenum and iron recycling from senescent erythrocytes by tissue macrophages. The recently identified hepatic peptide hepcidin has been proposed to be central to this regulation, acting as the principal iron-regulatory hormone to maintain iron homeostasis. Hepcidin is a 25-amino acid peptide synthesized by the liver, secreted into the bloodstream, and excreted by the kidney.^{1,2} Hepcidin expression is increased in iron overload³ and decreased in iron deficiency.^{4,5} Hepcidin-deficient mice accumulate iron in parenchymal cells with sparing of the reticuloendothelial system⁶ and, conversely, transgenic mice constitutively expressing hepcidin have markedly lower iron stores resulting in severe anemia.⁷ In humans, the important physiologic role of hepcidin was demonstrated by the identification of homozygous mutations of the hepcidin gene in patients with juvenile hemochromatosis,⁸ a severe iron overload disorder characterized by increased intestinal iron absorption, increased serum iron, and deposition of excess iron in parenchymal cells. Together,

these observations are all consistent with that idea that hepcidin is a key regulator of iron homeostasis that acts by limiting both intestinal iron absorption and macrophage iron release. Recent studies indicate that, to achieve this function, hepcidin binds to ferroportin,⁹ a transmembrane iron transporter necessary for iron export out of intestinal epithelial cells and macrophages.¹⁰ Hepcidin binding induces internalization of ferroportin and its subsequent degradation.⁹

In humans, hepcidin dysregulation was demonstrated in 2 phenotypically opposite iron disorders, hereditary hemochromatosis (HH) and the anemia of inflammation (also referred to as the anemia of chronic disease). Hepcidin production was reported to be deficient in patients with HH attributable to mutations in *HFE*, *TFR2*, or *HFE2*,¹¹⁻¹³ thus explaining their persistently increased iron absorption in the face of iron overload. In contrast, excessive hepcidin production was reported in patients with inflammatory and infectious disorders associated with the anemia of inflammation.^{14,15} Increased hepcidin expression is expected to rapidly sequester iron in the macrophages and inhibit duodenal iron absorption, 2 hallmarks of the anemia of inflammation.

From the Institut Cochin, Département de Génétique, Développement et Pathologie Moléculaire, Paris; Institut National de la Santé et de la Recherche Médicale (INSERM) U567, Centre National de Recherche Scientifique (CNRS) Unité mixte de Recherche (UMR) 8104, Université Paris Descartes, Faculté de Médecine René Descartes, UMR-S 8104, Paris; Institut National de la Transfusion Sanguine, Inserm U665, Paris; Inserm U409, Faculté de Médecine Xavier Bichat, Paris, France; Zentrum für Molekuläre Biologie, Heidelberg, Germany; and Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Howard Hughes Medical Institute, Boston, MA.

Submitted October 12, 2005; accepted November 23, 2005. Prepublished online as *Blood* First Edition Paper, December 8, 2005; DOI 10.1182/blood-2005-10-4071.

Supported by Inserm and the French Ministry of Education and Research ("Action Concertée Incitative"). D.-Q.L. and J.-C.L.-B. received grants from Agence Nationale de la Valorisation de la Recherche (ANVAR).

L.V. designed and performed research, analyzed data, and wrote the paper; G.N. designed and performed research; D.-Q.L. analyzed data; M.B. performed research; J.-C.L.-B. performed research; N.C.A. provided a mouse model and wrote the paper; K.S. provided a mouse model; H.B. provided a mouse model; F.C.-H. contributed key reagents; A.K. analyzed data; and S.V. designed research, analyzed data, and wrote the paper.

An Inside *Blood* analysis of this article appears at the front of this issue.

Reprints: Sophie Vaumont, Institut Cochin, Faculté de Médecine Cochin Port Royal, 24, rue du Faubourg Saint Jacques 75014 Paris, France; e-mail: vaumont@cochin.inserm.fr.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2006 by The American Society of Hematology

Recently, transgenic and mutant mouse models with hepcidin deficiency have provided significant insights into the important role of the hepcidin-ferroportin axis in iron metabolism.¹⁶⁻¹⁹ In these models, hepcidin deficiency correlated with up-regulated ferroportin protein in enterocytes, leading to increased intestinal iron absorption and increased plasma iron levels. In contrast, there have been few models developed to study the effects of hepcidin overexpression. We previously reported a transgenic mouse model in which the transthyretin (TTR) promoter was used to drive constitutive hepcidin synthesis.²⁰ Due to the very early activity of the TTR promoter in the fetal liver, the majority of the transgenic pups died within a few hours after birth from systemic iron deficiency associated with severe microcytic, hypochromic anemia. This phenotype suggested a hepcidin-dependent blockade of placental iron transport resulting from transgenic fetal hepcidin production late in gestation, when the endogenous hepcidin gene is not detectably expressed. To circumvent the early effects of hepcidin, we developed a conditional transgenic mouse model using a tetracycline-dependent inducible system (Tet ON).²¹ This model allows overexpression of hepcidin in the liver in response to doxycycline (a tetracycline analog) treatment, allowing investigation of the effects of hepcidin on iron absorption and recycling in adult animals. Here, we report the effects of induced transgenic hepcidin expression on iron homeostasis in normal mice and mice with genetic hemochromatosis (*Hfe*^{-/-} mice).

Materials and methods

Animals

All mice used in the experiments were cared for according to criteria outlined by the European Convention for the Protection of Laboratory Animals. Animals were maintained in a temperature- and light-controlled environment and were given free access to tap water and standard laboratory mouse food (AO3, iron content 280 mg/kg, UAR, Epinay-sur-Orge, France). Only male mice were used in this study.

Generation of transgenic mice

Null *Hfe*-deficient mice (*Hfe*^{-/-} mice) have been described previously.²² Full-length murine *Hepc1* cDNA was amplified using the forward primer 5'-GGGGGATATCAGGCCTCTGCACAGCAGAAGG-3' and the reverse primer 5'-GGGGGATATCAGGCCTCTATGTTTGAACAGATACC-3'. The *Hepc1* polymerase chain reaction (PCR) fragment was subcloned into the P_{tet}bi-1 plasmid (Clontech, Palo Alto, CA) containing a minimal CMV promoter regulated by a tet operator sequence, *tetO*, which is responsive to the regulatory rTA transactivator. The construct was confirmed by DNA sequence analysis. The 3.4-kbp *tetO-Hepc1* transgene was separated from the plasmid sequence by digestion with *AseI* and used for pronuclear microinjection. rTA^{LAP-1} mice, in which rTA is driven by the liver activator protein (LAP) promoter, were described previously.²³ Both transgenic lines (*tetO-Hepc1* and rTA^{LAP-1}) had mixed genetic backgrounds that included contributions from C57BL/6, 129/Sv, and DBA/2 strains.

Mice harboring only one of the 2 transgenes (either *tetO-Hepc1* or rTA^{LAP-1}) were used as controls because they do not express transgenic hepcidin. Mice harboring both transgenes (*tetO-Hepc1*/rTA^{LAP-1} mice), referred to as "inducible mice," expressed transgenic hepcidin after doxycycline treatment.

Inducible mice were crossed with *Hfe*^{-/-} mice, to generate inducible/*Hfe*^{+/-} mice (ie, *tetO-Hepc1*/rTA^{LAP-1}/*Hfe*^{+/-} mice). Inducible/*Hfe*^{+/-} mice were then intercrossed to generate inducible/*Hfe*^{-/-} mice (ie, *tetO-Hepc1*/rTA^{LAP-1}/*Hfe*^{-/-} mice). In this set of experiments littermates with *tetO-Hepc1*/*Hfe*^{+/-}, rTA^{LAP-1}/*Hfe*^{+/-}, *tetO-Hepc1*/*Hfe*^{+/+}, or rTA^{LAP-1}/*Hfe*^{+/+} genotypes were considered controls and animals with *tetO-Hepc1*/*Hfe*^{-/-} and rTA^{LAP-1}/*Hfe*^{-/-} genotypes were considered *Hfe*^{-/-} mice.

Genotyping of transgenic mice by PCR analysis and Southern blotting

Southern blot genotyping of *tetO-Hepc1* mice was done as described.⁷ *AseI*-digested DNA was electrophoresed, transferred to a nylon membrane (Hybond-N, Amersham Life Sciences, Saclay, France), and hybridized with a probe corresponding to the 3.4-kb *AseI* fragment of the *tetO* plasmid. The probe was labeled with [³²P]dCTP by random priming with a commercially available kit (Megaprime DNA labeling systems, Amersham Life Sciences).

gDNA (0.5-1 μg) was used in 50-μL PCRs. The *tetO-Hepc1* transgene was amplified using forward primer 5'-CGTGCTAGCGCGCCTC-GAC-3' (annealing to a sequence in multicloning site I of the P_{tet}bi-1 plasmid) and reverse primer 5'-AACAGATACCACACTGGAA-3' (annealing in *Hepc1* cDNA). The PCR was performed for 34 cycles (40 seconds at 94°C, 40 seconds at 60°C, and 40 seconds at 72°C), after initial denaturation at 94°C for 4 minutes, concluding with a final elongation step at 72°C for 5 minutes. A 297-bp-specific product corresponded to the *tetO-Hepc1* transgene. The rTA^{LAP-1} transgene was amplified using forward primer 5'-CCATGTCTAGACTGGACAAGA-3' and reverse primer 5'-CTCCAGGCCACATATGATTAG-3'. The PCR was performed for 37 cycles (30 seconds at 94°C, 60 seconds at 57°C, and 30 seconds at 72°C) after initial denaturation at 94°C for 4 minutes, concluding with a final elongation step at 72°C for 5 minutes. PCRs were carried out in 20 mM Tris HCl (pH 8.4), 50 mM KCl, 0.05% W-1, 2 mM MgCl₂, 0.2 mM each dNTP, 0.2 μM of each primer, and 4 U *Taq* polymerase (Invitrogen, Karlsruhe, Germany). The reaction mixtures were analyzed on 1.5% agarose gels containing ethidium bromide. Genotyping results from Southern blot and PCR analyses were consistent. Finally, *Hfe* genotyping was performed using primers specific for the wild-type *Hfe* allele (forward 5'-TTCTTTA-GATAGCCTCTCAC-3' and reverse 5'-GTGGGAGTCACTTTCACCA-3') and the targeted *Hfe* allele (forward 5'-AGTTGGGAGTGGTGTC-CGA-3' and reverse 5'-CTAGCTTCGGCCGTGACG-3'), resulting in 502-bp and 190-bp products, respectively. The PCR was performed for 40 cycles (30 seconds at 94°C, 56 seconds at 56°C, and 30 seconds at 72°C) after initial denaturation at 94°C for 4 minutes, concluding with a final elongation step at 72°C for 5 minutes.

Doxycycline administration

Doxycycline, a derivative of tetracycline, is the substance of choice for the induction of the Tet ON system. Mice of all genotypes were treated with doxycycline. For short-term induction, doxycycline hydrochloride (Sigma-Aldrich, Lyon, France) was freshly dissolved in 0.9% NaCl at a final concentration of 4 mg/mL and filter-sterilized prior to intraperitoneal injection. A dose of 2 mg doxycycline was given once to each mouse.

For long-term induction, doxycycline hydrochloride (2 mg/mL final concentration) and sucrose (3% final concentration) were dissolved in distilled sterile water and administered ad libitum from foil-covered water bottles. The doxycycline-sucrose solution was prepared fresh every 3 to 4 days.

Hematologic analysis

Blood was sampled by retro-orbital phlebotomy into heparinized tubes (Capiject T-MLH, Laboratories Terumo, Guyancourt, France) before the mice were humanely killed. Blood cell counts and erythrocyte parameters were determined using a MaxM Coulter automatic analyzer (Coulter, Hialeah, FL).

Northern blotting

Total RNA from mouse tissues was isolated using RNAsplu (QBiogene, Illkirch, France). Liver RNA (20 μg) was denatured in formaldehyde-containing buffer and electrophoresed through 1% agarose, 2.2 M formaldehyde gels. Northern blot analysis was performed as previously described.^{6,24} Briefly, after electrophoresis, RNA was transferred to a nylon membrane (GeneScreen Plus, Perkin Elmer Life Sciences, Courtabouef, France) in 20 × SSC buffer and probed simultaneously with cDNA probes specific for hepcidin and ribosomal 18S mRNAs. The probe used to detect

hepcidin was prepared from a plasmid isolated by suppressive subtractive hybridization, pT-Adv/Hepc1.⁶

Iron measurements

Quantification of serum or liver iron content was performed as previously described by Torrance and Bothwell²⁵ using the IL test (Instrumentation Laboratory, Lexington, MA) on an Olympus AU400 automat. For histology, tissues were fixed in 4% formaldehyde, embedded in paraffin, mounted onto slides, and stained with Prussian blue and nuclear red counterstain using standard procedures. For Perls 3,3-diaminobenzidine tetrahydrochloride (DAB) staining, tissue sections were incubated for 20 minutes in 1% H₂O₂ in 0.1 M PBS, immersed in Perls solution (1:1, 2% HCl and 2% potassium ferrocyanide) at room temperature for 30 minutes, and then incubated for 10 minutes in 0.015% H₂O₂ in DAB.

Immunoblotting

Microsomal and cytosolic fractions from frozen tissues of 3-month-old mice were prepared as previously described.¹⁶ Cytosolic protein (20 μg) solubilized in 1 × Laemmli buffer and incubated for 30 minutes at room temperature (RT), or 20 to 50 μg microsomal protein solubilized in 1 × Laemmli buffer and incubated for 5 minutes at 100°C was electrophoresed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF filters. Ponceau red staining confirmed similar gel loading and similar transfer of proteins to the membranes. Immunoblots were preincubated with blocking solution (7% skim milk in 0.15% Tween 20 in Tris-buffered saline [TBST]) prior to incubation with primary antibodies. Rabbit polyclonal anti-mouse ferroportin antibody was previously described^{16,18} and rabbit polyclonal anti-mouse L-ferritin antibody was a kind gift from P. Santambrogio and S. Levi.²⁶ Antibodies were diluted in blocking solution as follows: anti-mouse ferroportin, 1:600, and anti-mouse L-ferritin, 1:1000. After incubation with antibodies, membranes were washed in TBST and then incubated with peroxidase-labeled anti-rabbit immunoglobulin (1:8000, Amersham Life Sciences). Signals were visualized by enhanced chemiluminescence (Supersignal West Pico; Perbio Science France, Brebières, France).

Immunohistochemistry

Tissues from 3-month-old mice were fixed in 4% formaldehyde. Paraffin sections were subjected to microwave treatment and then processed for immunohistochemistry using the EnVision+ System-HRP (DAB) kit (Dako, Trappes, France) according to the manufacturer's recommendations. Primary antibody against ferroportin was diluted 1:75 before use. As a negative control, immunohistochemistry with no primary antibody was performed (not shown).

Results

Generation of a mouse line controlling hepcidin expression

To inducibly express transgenic hepcidin we chose a tetracycline-dependent Tet ON system that permits quantitative and deliberately regulated control of gene activity in the liver (Figure 1A). To develop transgenic mice, *Hepc1* cDNA controlled by the tet operator (*tetO-Hepc1* transgene) was transferred into mice by pronucleus injection and 11 potential founder animals carrying the transgene were generated. To select for the best trans-responder line, the *tetO-Hepc1* mice were crossed with rTA^{LAP-1} mice (previously described, see Schonig et al²³), harboring the coding sequence of the tetracycline-dependent transactivator under the control of a liver-specific promoter (LAP). The mothers were given doxycycline (2 mg/mL in 3% sucrose) in their drinking water from day 7 after birth until weaning to induce transgenic hepcidin expression in the breastfeeding pups. Expression of the *Hepc1* transgene was analyzed in offspring carrying both transgenes by assessing liver transgenic hepcidin mRNA on Northern blots. Of the 11 lines examined, only one showed high levels of transgenic *Hepc1* mRNA expression. This line was selected for further study.

Short-term induction of transgenic hepcidin causes hypoferremia

Short-term expression of transgenic hepcidin was induced in 2-month-old inducible mice (ie, double transgenic mice harboring both *tetO-Hepc1* and rTA^{LAP-1} transgenes) by a single intraperitoneal injection of doxycycline. Mice were humanely killed 3, 6, 9, or 18 hours after injection. Liver hepcidin mRNA levels were assessed by Northern blot and serum iron was determined. As shown in Figure 1B, transgenic hepcidin mRNA (Thepc, distinguished from endogenous hepcidin mRNA by its longer β-globin polyA) was detected as early as 3 hours after doxycycline injection. It reached a maximum level at 9 hours and then declined by 18 hours after injection. Doxycycline induction of transgenic hepcidin was associated with decreased serum iron level beginning after 6 hours and lasting up to 18 hours (Figure 1C). Of interest, expression of endogenous hepcidin was repressed 3 hours after serum iron level decreased (ie, 9 hours after injection of doxycycline).




Figure 1. Development of mice expressing an inducible hepcidin transgene. (A) Schematic outline of the Tet ON regulatory system. The rTA protein acts as a strong transcriptional activator in the presence of doxycycline by binding to its cognate operator sequence (*tetO*). (B) Hepcidin mRNA levels in the livers of control mice and inducible mice (ie, double transgenic mice harboring both *tetO-Hepc1* and rTA^{LAP-1} transgenes), 3, 6, 9, or 18 hours after a single intraperitoneal injection of doxycycline. Total liver RNA (20 μg) was fractionated by electrophoresis, blotted, and hybridized with hepcidin and 18S-labeled probes. A typical experiment is shown. (C) Serum iron levels (μM) in animals injected with doxycycline 3, 6, 9, or 18 hours after treatment. Results are expressed relative to control serum iron (arbitrarily 100 ± standard deviation). Control animals, □; inducible mice, ■. Statistical analysis was performed using Student *t* test (unpaired, 2 tailed): **P* < .05, at least 3 animals. Thepc indicates transgenic hepcidin mRNA; endo hepc, endogenous hepcidin mRNA.




Figure 2. Long-term induction of transgenic hepcidin. (A) Liver hepcidin mRNA levels. Control mice and inducible mice (ie, double transgenic mice harboring both *tetO-Hepc1* and *rTA^{LAP-1}* transgenes) were given doxycycline in their drinking water for 3 weeks. Total liver RNA (20 μg) was fractionated by electrophoresis, blotted, and hybridized with hepcidin and 18S-labeled probes. Values for RBC count, hemoglobin (HGB) level, and serum iron level are shown for each animal. Thepc indicates transgenic hepcidin mRNA; endo hepc, endogenous hepcidin mRNA. (B) Hematologic indices of mice treated for 10, 14, or 20 days with doxycycline. Results are expressed relative to control serum parameters (arbitrarily 100 ± standard deviation). Control animals, □; inducible mice, ■. Statistical analysis was performed using Student *t* test (unpaired, 2 tailed): **P* < .05, *n* = at least 5 animals. RBC indicates red blood cell count (10⁶/μL); HGB, hemoglobin (g/dL); HCT, hematocrit (%); MCV, mean cell volume (fl).

Long-term induction of transgenic hepcidin results in iron-restricted erythropoiesis

Long-term induction of transgenic hepcidin was achieved by administering doxycycline to inducible mice in their drinking water. After 3 weeks of treatment, high levels of transgenic hepcidin mRNA were detected in the livers of the inducible mice (Figure 2A). As a consequence, these mice developed iron-restricted erythropoiesis and anemia as demonstrated by decreased levels of serum iron and hemoglobin and red blood cell (RBC) numbers (Figure 2A). The sustained expression of transgenic hepcidin resulted in decreased levels of the endogenous hepcidin mRNA (Figure 2A), as previously reported in mice constitutively expressing transgenic hepcidin.⁷ To assess the time course of the development of anemia in inducible mice, blood was sampled and analyzed at different time points during the 3-week treatment (Figure 2B). Hematologic indices tended to change 10 days after induction. Decreased values became significant for all hematologic parameters after 2 weeks of doxycycline treatment and lasted for at least 3 weeks. The effect of a 2-week doxycycline course was reversible, with RBC and hemoglobin levels returning to control values 10 days after doxycycline withdrawal (not shown).

Transgenic hepcidin induces an altered pattern of iron distribution in *Hfe*^{-/-} mice

We next asked whether hepcidin-induced iron depletion might alter the pattern of cellular iron accumulation seen in hereditary hemochromatosis. To this end, inducible mice were crossed with *Hfe*^{-/-} mice. Inducible/*Hfe*^{+/-} offspring were intercrossed to yield inducible/*Hfe*^{-/-} mice (ie, mice harboring both *tetO-Hepc1* and *rTA^{LAP-1}* transgenes and with *Hfe*^{-/-} genotype). Two-month-old animals (control, *Hfe*^{-/-} and inducible/*Hfe*^{-/-} mice) were given doxycycline in their drinking water for 3 weeks.

As compared to control mice, *Hfe*^{-/-} mice had increased serum iron levels (43 ± 3 μM in *Hfe*^{-/-} mice, *n* = 3 versus 30 ± 9 in control mice, *n* = 5; *P* = .05), increased liver iron content (471 ± 166 μg iron/g wet tissue in *Hfe*^{-/-} mice, *n* = 3 versus 127 ± 33 in control mice, *n* = 6; *P* = .0012), and concomitant accumulation of liver L-ferritin proteins (as assessed by immunoblot; Figure 3B). Ferritin levels in the spleens of *Hfe*^{-/-} mice were, as in control mice, at the limit of detection. Finally, as previously reported,^{11,20,27,28} hepatic endogenous hepcidin mRNA levels were inappropriately low relative to the iron burden in *Hfe*^{-/-} mice (Figure 3A).

High levels of transgenic hepcidin mRNA were detected in inducible/*Hfe*^{-/-} mice; endogenous hepcidin mRNA was undetectable (Figure 3A). Similar to inducible transgenic mice with wild-type *Hfe* alleles, inducible/*Hfe*^{-/-} mice had severe hypoferrremia (5 ± 2.5 μM in inducible/*Hfe*^{-/-} mice, *n* = 5 versus 43 ± 3 μM in *Hfe*^{-/-} mice, *n* = 5; *P* < .001) and developed signs of




Figure 3. Characterization of mice carrying the inducible hepcidin transgenes crossed with *Hfe*^{-/-} mice after treatment for 3 weeks with doxycycline. In this figure, each column represents the same animal. (A) Hepcidin mRNA levels in the livers of control (cont), *Hfe*^{-/-} and inducible/*Hfe*^{-/-} mice (ind/*Hfe*^{-/-}, ie, mice harboring both *tetO-Hepc1* and *rTA^{LAP-1}* transgenes and with *Hfe*^{-/-} genotype) treated for 3 weeks with doxycycline. Total liver RNA (20 μg) was fractionated by electrophoresis, blotted, and hybridized with hepcidin and 18S-labeled probes. (B) Ferritin and ferroportin levels as assessed by immunoblot analysis of livers and spleens of control, *Hfe*^{-/-} and ind/*Hfe*^{-/-} mice treated for 3 weeks with doxycycline. Anti-mouse L-ferritin antibody was used to probe 20 μg hepatic (top panel) or splenic (bottom panel) cytosolic extract. Anti-mouse ferroportin antibody was used to probe 50 μg hepatic (top panel) or 20 μg splenic (bottom panel) microsomal extract. Molecular weight markers (kDa) are indicated on the left. The levels of serum iron and liver iron are shown for each animal.

iron-restricted erythropoiesis. Surprisingly, total liver nonheme iron content and liver L-ferritin protein levels were similar in mice of both genotypes ($472 \pm 166 \mu\text{g}$ iron/g wet tissue in inducible/*Hfe*^{-/-} mice, $n = 5$ versus 485 ± 169 in *Hfe*^{-/-} mice, $n = 5$; Figure 3B). However, Perls staining of liver sections indicated that, although total liver iron content was unchanged, induction of hepcidin in inducible/*Hfe*^{-/-} mice resulted in an altered pattern of cellular iron accumulation. Indeed, whereas iron was primarily detected in hepatocytes of *Hfe*^{-/-} mice, iron was predominantly found in tissue macrophages (Kupffer cells) in inducible/*Hfe*^{-/-} mice (Figure 4A, panel i versus panel iii). Similarly, splenic macrophage iron content was increased in inducible/*Hfe*^{-/-} mice as shown by increased splenic L-ferritin levels (Figure 3B) and markedly enhanced Perls staining of splenic red pulp macrophages (Figure 4A, panel iv versus panel ii).

Altered pattern of iron distribution is associated with changes in ferroportin expression

Because ferroportin is a major target of hepcidin,⁹ we examined ferroportin expression in inducible/*Hfe*^{-/-} mice using immunoblotting and immunohistochemistry. In the livers of control mice, ferroportin is normally expressed at low levels (Figure 3B). Its expression was increased in the livers of *Hfe*^{-/-} mice, due to enhanced expression of ferroportin in Kupffer cells (Figure 4Bi). The sustained expression of hepcidin in the inducible/*Hfe*^{-/-} mice leads to a decrease in ferroportin in Kupffer cells as observed by both immunoblot analysis and immunohistochemistry (Figures 3B and 4B, panel iii versus panel i). Ferroportin expression varied in a similar fashion in splenic macrophages, with increased levels in *Hfe*^{-/-} mice and decreased levels in inducible/*Hfe*^{-/-} mice (Figures 3B and 4B, panel iv versus panel ii).

To assess the effect of transgenic hepcidin expression on intestinal iron absorption, Perls DAB staining and ferroportin immunodetection were used to evaluate the duodenum of *Hfe*^{-/-} and inducible/*Hfe*^{-/-} mice.

Whereas ferroportin was clearly detected at the basolateral membrane of the absorptive enterocytes lining the intestinal villi of the *Hfe*^{-/-} mice, a marked decrease in the amount of ferroportin was observed in inducible/*Hfe*^{-/-} mice (Figure 4C, panel i versus panel iii). Concomitantly, there was a strong increase in the amount of stainable iron present in duodenal enterocytes in inducible/*Hfe*^{-/-} mice as compared to *Hfe*^{-/-} mice (Figure 4C, panel iv versus panel ii).

Discussion

We report the characterization of a new mouse model that allows inducible expression of the iron-regulatory hormone hepcidin. The effect of short-term induction of hepcidin was evaluated by giving a single dose of the inducer doxycycline to mice carrying transgenes mediating hepcidin expression. We found that induction was associated with decreased serum iron within 6 hours, consistent with a direct role of murine hepcidin in vivo in the development of hypoferremia. This result is in accord with the recent work of Rivera et al who demonstrated that injection of synthetic human hepcidin triggered hypoferremia in mice 1 hour later.²⁹ The delay in decreased serum iron observed in our model is likely explained by the time needed for transactivation, transcription, and processing of hepcidin prior to its secretion in the bloodstream. The rapid effect of hepcidin in these models is most likely due to blockade of export of recycled iron from macrophages, a process that supplies most of




Figure 4. Perls staining and tissue ferroportin protein levels of liver, spleen, and duodenum sections from mice carrying the inducible hepcidin transgenes crossed with *Hfe* knockout (*Hfe*^{-/-}) mice and treated for 3 weeks with doxycycline. (A-B) Typical Perls staining (A) and ferroportin immunodetection (B) using anti-mouse ferroportin antibody of liver (i,iii; original magnification $\times 40$ in panel A and $\times 20$ in panel B) and spleen (ii,iv; original magnification $\times 10$) sections from *Hfe*^{-/-} (i-ii) and *ind/Hfe*^{-/-} mice (ie, mice harboring both *tetO-Hepc1* and *rTALAP-1* transgenes and with *Hfe*^{-/-} genotype; iii-iv). Nonheme iron stains blue. The liver iron content for each animal is shown. (C) Duodenum (original magnification $\times 20$) was stained for iron (ii,iv, Perls DAB staining, nonheme iron stains brown) and ferroportin (i,iii) immunodetection in *Hfe*^{-/-} (i-ii) and in *ind/Hfe*^{-/-} mice (ie, mice harboring both *tetO-Hepc1* and *rTALAP-1* transgenes and with *Hfe*^{-/-} genotype; iii,iv). All microscopy was performed using a Nikon Eclipse E800 microscope equipped with $10\times/0.45$, $20\times/0.75$, and $40\times/0.95$ oil-immersion objective lenses. Digital images were captured with a Nikon DXM1200 camera, and were acquired and processed with Nikon AC7-1 2.63 software (all from Nikon France, Champigny-sur-Mame, France).

the iron needed for erythropoiesis. Heparin-induced hypoferrremia lasted at least 18 hours after a single dose of inducing drug in our transgenic model, a time-course effect that is compatible with that reported by Rivera et al using human radiolabeled hepcidin.²⁹

The mechanism of regulation of hepcidin gene expression in response to iron status is not yet known. It was recently proposed that circulating diferric transferrin may directly regulate hepcidin gene expression and that transferrin receptor 2 (TFR2) is responsible for homeostatic iron sensing by the liver (for a review, see Frazer and Anderson³⁰). Our observation that endogenous hepcidin gene expression was decreased 3 hours after serum iron decreased is consistent with the hypothesis that decreased iron bound to transferrin is involved in rapid down-regulation of hepcidin synthesis.

To study the chronic effects of hepcidin, chronic induction was achieved by giving doxycycline in the drinking water. Under these conditions, mice carrying the inducible transgene showed iron retention in the macrophages (data not shown) and developed iron-limited erythropoiesis 2 weeks after treatment. These characteristics are reminiscent of anemia of inflammation (also referred to as anemia of chronic disease) as already discussed by Rivera et al.³¹ These authors reported that mice given implants with tumor xenografts engineered to overexpressed human hepcidin developed severe anemia.³¹ However, although those authors reported that hepcidin was shunting iron away from erythropoiesis by sequestering it predominantly in hepatocytes, we were unable to detect a significant amount of iron in the hepatocytes of our inducible mice (data not shown). Instead, iron was sequestered in macrophages as demonstrated for the inducible/*Hfe*^{-/-} mice. This discrepancy may be explained by the different mouse strains and the complexity of the model used by Rivera and colleagues, who introduced hepatoma tumor cells into immunodeficient NOD-SCID mice maintained on a high-iron diet.³¹

We previously reported that hepcidin could prevent iron overload in HFE-associated hemochromatosis by crossing transgenic mice constitutively expressing hepcidin TTR-*Hepcl* mice with *Hfe*^{-/-} mice.²⁰ However, to consider possible therapy for affected patients, it was important to determine whether hepcidin treatment would be beneficial after iron overload was established. Indeed, hemochromatosis remains substantially underdiagnosed and, if untreated, can cause serious illness with complications including liver cirrhosis, fibrosis, and hepatocellular carcinoma. It could be advantageous to manipulate iron homeostasis in patients with more advanced disease.

Therefore, we used an inducible transgene to effect chronic hepcidin replacement in adult animals that already had increased liver iron deposition. We demonstrated that supplementary expression of hepcidin in our murine hemochromatosis model leads to an altered pattern of cellular iron accumulation. Iron sequestration in the macrophage is associated with, and likely explained by, hepcidin-induced ferroportin degradation. The link between ferroportin and hepcidin was first established by Nemeth et al, who demonstrated *ex vivo* that hepcidin was able to bind to ferroportin,

thereby inducing internalization and degradation of ferroportin, resulting in decreased export of cellular iron.⁹ This finding has been replicated in several transfected cell lines³²⁻³³ and, more recently, in bone marrow-derived macrophages expressing endogenous ferroportin.³⁴ In this study, we observed iron retention in splenic macrophages and enterocytes of *Hfe*^{-/-} mice induced to express hepcidin, providing further evidence that hepcidin-induced ferroportin degradation explains the pleiotropic effects of hepcidin in the regulation of iron homeostasis *in vivo*.

The altered pattern of iron distribution in *Hfe*^{-/-} mice expressing the hepcidin transgene is the phenotypic opposite of the liver iron overload that occurs in genetic hemochromatosis associated with insufficient hepcidin. Interestingly, hepatocyte ferroportin expression is not appreciably different from normal in either case.^{16,17} It is tempting to speculate that hepatocyte iron egress is governed by a hepcidin-ferroportin independent pathway. Alternatively, there may be distinct mechanisms for regulating ferroportin expression or activity (or both) in hepatocytes. However, ferroportin protein is difficult to detect in hepatocytes under normal conditions, and it remains possible that subtle changes in ferroportin expression would be impossible to discern under our experimental conditions.

Iron accumulation in splenic macrophages and consequent decreased serum iron in *Hfe*^{-/-} mice expressing the inducible hepcidin transgene is reminiscent of the clinical features of patients with autosomal dominant iron overload due to pathogenic mutations in the ferroportin gene (for a review, see Pietrangelo³⁵). In most cases, ferroportin mutations result in loss of protein function. Patients typically present with increased iron deposition in Kupffer cells (rather than hepatocytes) and low serum transferrin saturation. Some do not tolerate phlebotomy and develop a mild anemia.³⁶⁻³⁸ Furthermore, in contrast to the other forms of hemochromatosis associated with hepcidin deficiency, hepcidin levels are elevated in these patients.³⁹ These patients rarely develop liver fibrosis or cirrhosis and they have few, if any, clinical manifestations of iron-storage disease. As recently suggested by Zoller et al, it appears that iron deposition in Kupffer cells is well tolerated.⁴⁰ Based on these observations, we speculate that the altered pattern of cellular iron distribution following hepcidin treatment could ameliorate hemochromatosis by reducing iron-induced damage of parenchymal cells. Furthermore, the hepcidin-induced down-regulation of ferroportin and iron retention that we observed in enterocytes suggest that further iron absorption will be abrogated, thus preventing additional body iron accumulation. This result contrasts with studies of patients with 3 different types of ferroportin mutations, in which no enterocyte iron retention was observed.⁴¹

In conclusion, our results provide further support for the attractive hypothesis that hepcidin acts to decrease intestinal iron absorption and iron egress from the macrophages by down-regulating ferroportin. It provides a rationale for using hepcidin or a hepcidin agonist in the treatment of iron overload disorders.

References

- Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett*. 2000; 480:147-150.
- Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*. 2001;276:7806-7810.
- Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem*. 2001;276:7811-7819.
- Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. *J Clin Invest*. 2002;110:1037-1044.
- Frazer DM, Wilkins SJ, Becker EM, et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. *Gastroenterology*. 2002;123: 835-844.
- Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2)

- knockout mice. *Proc Natl Acad Sci U S A*. 2001;98:8780-8785.
7. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. *Proc Natl Acad Sci U S A*. 2002;99:4596-4601.
 8. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. *Nat Genet*. 2003;33:21-22.
 9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science*. 2004;306:2090-2093.
 10. Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. *Cell Metab*. 2005;1:191-200.
 11. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. *Lancet*. 2003;361:669-673.
 12. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. *Blood*. 2005;105:1803-1806.
 13. Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. *Nat Genet*. 2004;36:77-82.
 14. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JL, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. *Blood*. 2002;100:3776-3781.
 15. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101:2461-2463.
 16. Viatte L, Lesbordes-Brion JC, Lou DQ, et al. Down-regulation of proteins involved in iron metabolism in hepcidin-deficient mice. *Blood*. 2005;105:4861-4864.
 17. Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. *J Clin Invest*. 2005;115:2187-2191.
 18. Canonne-Hergaux F, Donovan A, Delaby C, Wang H-j, Gros P. Comparative studies of duodenal and macrophage ferroportin proteins. *Am J Physiol Gastrointest Liver Physiol*. 2005;290:156-163.
 19. Mok H, Jelinek J, Pai S, et al. Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythemia mice. *Development*. 2004;131:1859-1868.
 20. Nicolas G, Viatte L, Lou DQ, et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. *Nat Genet*. 2003;34:97-101.
 21. Kistner A, Gossen M, Zimmermann F, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc Natl Acad Sci U S A*. 1996;93:10933-10938.
 22. Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. *Blood*. 1999;94:9-11.
 23. Schonig K, Schwenk F, Rajewsky K, Bujard H. Stringent doxycycline dependent control of CRE recombinase in vivo. *Nucleic Acids Res*. 2002;30:e134.
 24. Lou DQ, Nicolas G, Lesbordes JC, et al. Functional differences between hepcidin 1 and 2 in transgenic mice. *Blood*. 2004;103:2816-2821.
 25. Torrance JD, Bothwell TH. Tissue iron stores. *Methods Hematol*. 1980;1:90-115.
 26. Santambrogio P, Cozzi A, Levi S, et al. Functional and immunological analysis of recombinant mouse H- and L-ferritins from *Escherichia coli*. *Protein Expr Purif*. 2000;19:212-218.
 27. Ahmad KA, Ahmann JR, Migas MC, et al. Decreased liver hepcidin expression in the Hfe knockout mouse. *Blood Cells Mol Dis*. 2002;29:361-366.
 28. Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. *Nat Genet*. 2003;34:102-107.
 29. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferrremia and is concentrated in ferroportin-containing organs. *Blood*. 2005;106:2196-2199.
 30. Frazer DM, Anderson GJ. Iron imports. I. Intestinal iron absorption and its regulation. *Am J Physiol Gastrointest Liver Physiol*. 2005;289:G631-G635.
 31. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. *Blood*. 2005;105:1797-1802.
 32. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. *Proc Natl Acad Sci U S A*. 2005;102:1324-1328.
 33. Drakesmith H, Schimanski LM, Ormerod E, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. *Blood*. 2005;106:1092-1097.
 34. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. *Blood*. 2005;106:3979-3984.
 35. Pietrangelo A. The ferroportin disease. *Blood Cells Mol Dis*. 2004;32:131-138.
 36. Jouanolle AM, Douabin-Gicquel V, Halimi C, et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. *J Hepatol*. 2003;39:286-289.
 37. Wallace DF, Browett P, Wong P, Kua H, Ameratungu R, Subramanian VN. Identification of ferroportin disease in the Indian subcontinent. *Gut*. 2005;54:567-568.
 38. Morris TJ, Litvinova MM, Ralston D, Mattman A, Holmes D, Lockitch G. A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis. *Blood Cells Mol Dis*. 2005;35:309-314.
 39. Papanikolaou G, Tzilianos M, Christakis JJ, et al. Hepcidin in iron overload disorders. *Blood*. 2005;105:4103-4105.
 40. Zoller H, McFarlane I, Theurl I, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. *Hepatology*. 2005;42:466-472.
 41. Corradini E, Montosi G, Ferrara F, et al. Lack of enterocyte iron accumulation in the ferroportin disease. *Blood Cells Mol Dis*. 2005;35:315-318.